Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company located in the western Philadelphia suburb of Exton. We are passionately focused on the development and commercialization of our proprietary immune modulator, tilsotolimod, for the treatment of cancer. Tilsotolimod, our toll-like receptor (TLR9) agonist has now advanced to Phase 3 clinical development in our lead indication anti-PD-1 refractory melanoma. Tilsotolimod is designed to prime the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy.

At Idera, we are proud to have been named a 2019 Best Place to Work by the Philadelphia Business Journal. We have a culture where patients are at the center of all we do, with core values that connect us to each other and define who we are, what we stand for, and how we work. If you are driven, collaborative, and share the common goal of addressing the unmet needs of patients suffering from rare, life-threatening diseases, come join our team!